Novavax (NVAX) Amortization of Deferred Charges (2016 - 2020)

Novavax's Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $356000.0 for Q4 2020.

• On a quarterly basis, Amortization of Deferred Charges changed 0.0% year-over-year to $356000.0 in Q4 2020; TTM through Dec 2020 was $1.4 million, a 0.0% change from a year earlier, with the FY2020 full-year figure at $1.4 million, changed 0.0% from the prior year.
• Amortization of Deferred Charges held at $356000.0 in Q4 2020 per NVAX's latest filing, from $356000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $949000.0 in Q3 2016 and bottomed at $237000.0 in Q1 2016.
• The 5-year median for Amortization of Deferred Charges is $356000.0 (2016), against an average of $381000.0.
• Biggest YoY gain for Amortization of Deferred Charges was 50.21% in 2017; the steepest drop was 62.49% in 2017.
• Year by year, Amortization of Deferred Charges stood at $949000.0 in 2016, then slumped by 62.38% to $357000.0 in 2017, then fell by 0.28% to $356000.0 in 2018, then changed by 0.0% to $356000.0 in 2019, then changed by 0.0% to $356000.0 in 2020.
• Per Business Quant, the three latest NVAX Amortization of Deferred Charges figures stand at $356000.0 (Q4 2020), $356000.0 (Q3 2020), and $356000.0 (Q2 2020).